August 18, 2026
QurAlis to Participate in Upcoming Investor Conferences in September
CAMBRIDGE, Mass., August 18, 2026 – QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that Kasper Roet, Ph.D., CEO and co-founder, will participate at the following investor conferences in September. Management will also participate in one-on-one investor meetings.
Wells Fargo Securities 21st Annual Healthcare Conference (September 10, 2026)
Format: Presentation; one-on-one investor meetings
Time: 10:15AM ET
Location: Boston, MA
Morgan Stanley 24th Annual Global Healthcare Conference (September 14, 2026)
Format: Presentation; one-on-one investor meetings
Time: 2:00PM ET
Location: New York, NY
13th Annual World Medical Innovation Forum (September 22-23, 2026)
Format: Panel: Rare But Not Forgotten / Strategies to Maximize Impact for Rare Disease Patients; one-on-one investor meetings
Date/Time: September 23, 2026; 2:30PM ET
Location: Boston, MA
Bank of America Healthcare Trailblazers Private Company Showcase Conference (September 24, 2026)
Format: One-on-one investor meetings
Location: Boston, MA
The QurAlis corporate presentation can be accessed by visiting the presentations section of the Company’s website at www.quralis.com.
About QurAlis Corporation
At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines. We work collaboratively with a relentless pursuit of knowledge, precise attention to craft, and compassion to discover and develop medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases. QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers. For more information, please visit www.quralis.com or follow us on X @QurAlisCo or LinkedIn.
